Last reviewed · How we verify
Decitabine plus Fludarabine and Busulfan
Decitabine plus Fludarabine and Busulfan is a Small molecule drug developed by Hackensack Meridian Health. It is currently in Phase 1 development.
At a glance
| Generic name | Decitabine plus Fludarabine and Busulfan |
|---|---|
| Sponsor | Hackensack Meridian Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- Platelet Count Decreased
- White Blood Cell Decreased
- Lymphocyte count decreased
- Neutrophil Count Decreased
- Febrile Neutropenia
- Fatigue
- Nausea
- Hypertension
- Anorexia
- Diarrhea
- Hypokalemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decitabine plus Fludarabine and Busulfan CI brief — competitive landscape report
- Decitabine plus Fludarabine and Busulfan updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI
Frequently asked questions about Decitabine plus Fludarabine and Busulfan
What is Decitabine plus Fludarabine and Busulfan?
Decitabine plus Fludarabine and Busulfan is a Small molecule drug developed by Hackensack Meridian Health.
Who makes Decitabine plus Fludarabine and Busulfan?
Decitabine plus Fludarabine and Busulfan is developed by Hackensack Meridian Health (see full Hackensack Meridian Health pipeline at /company/hackensack-meridian-health).
What development phase is Decitabine plus Fludarabine and Busulfan in?
Decitabine plus Fludarabine and Busulfan is in Phase 1.
What are the side effects of Decitabine plus Fludarabine and Busulfan?
Common side effects of Decitabine plus Fludarabine and Busulfan include Anemia, Platelet Count Decreased, White Blood Cell Decreased, Lymphocyte count decreased, Neutrophil Count Decreased, Febrile Neutropenia.